妊娠期COVID-19相关药物使用研究:COVI-PREG队列
基于COVI-PREG登记处纳入2020年3月至2021年7月SARS-CoV-2阳性孕妇1964例,描述抗生素、抗病毒药、羟氯喹、糖皮质激素等COVID-19相关药物的使用情况。总体10.4%使用至少一种相关药物,用药比例随疾病严重程度升高,2020年7月前高于之后(16.7% vs 7.7%)。
要点
- 孕妇COVID-19相关药物使用率随病情严重程度递增,无症状者3.1%,需插管者96.2%。
- 总体用药率10.4%,抗生素8.6%、糖皮质激素3.2%、抗病毒药2.0%、羟氯喹1.4%。
- 2020年7月前用药比例16.7%高于之后7.7%,抗生素、抗病毒药和羟氯喹后期使用减少。
核心结论
- 妊娠期COVID-19相关药物使用随疾病严重程度增加。
- 糖皮质激素使用增加趋势似与指南变化一致。
- 妊娠期COVID-19相关药物的有效性和安全性仍需证据。
研究设计与样本
- 基于COVI-PREG登记处的队列研究,纳入2020年3月至2021年7月SARS-CoV-2阳性孕妇1964例。
- 记录抗生素、抗病毒药、羟氯喹、糖皮质激素、抗白介素-6和免疫球蛋白暴露。
- 按妊娠 trimester、COVID-19严重程度和疫情早期/晚期(2020年7月1日前后)描述用药 prevalence。
主要发现
- 总体10.4%(205/1964)使用至少一种COVID-19相关药物。
- 抗生素使用率8.6%(169/1694),糖皮质激素3.2%(62/1964),抗病毒药2.0%(39/1964),羟氯喹1.4%(27/1964),抗白介素-6 0.3%(5/1964)。
- 至少一种药物使用率:无症状3.1%(12/381),门诊4.2%(52/1233),无氧住院19.7%(46/233),标准氧疗72.1%(44/61),高流量氧疗95.7%(22/23),插管96.2%(25/26),死亡57.1%(4/7)。
- 2020年7月前用药比例16.7%高于之后7.7%。
- 抗生素、抗病毒药和羟氯喹在疫情晚期使用率较低。
临床怎么用
- 临床用药决策应结合妊娠分期和COVID-19严重程度评估。
- 关注疫情时期指南变化对糖皮质激素等药物使用的影响。
- 妊娠期使用COVID-19相关药物需权衡有效性与安全性证据的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The objective of this study was to describe the use of COVID-19-related medicines during pregnancy and their evolution between the early/late periods of the pandemic. METHODS: Pregnant women who tested positive for SARS-CoV-2 from March 2020 to July 2021 were included using the COVI-PREG registry. Exposure to the following COVID-19-related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after 1 July 2020). FINDINGS: We included 1964 pregnant patients who tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19-related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19-related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period. CONCLUSION: Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19-related medicines in pregnancy.
引用
- Favre G, Gerbier E, Maisonneuve E, et al. COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort. Br J Clin Pharmacol. 2022. PMID: 36417423. doi:10.1111/bcp.15611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。